APGE

Apogee Therapeutics, Inc. Common Stock

APGE.US apogeetherapeutics.com
Price N/A
USD · NASDAQ
52-week range
35.39
135.09
Market Cap
10.22B
P/E Ratio
0.00
Forward P/E
0.00
Book Value
15.91
Div. Yield
N/A
% Institutions
110.81%
% Insiders
2.32%

1 Year

+254.0%

3 Year

+467.5%

10 Year

+694.5%
Description

Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulmonary disease and asthma; APG333, a half-life extended TSLP antibody; APG279, a combination therapy for atopic dermatitis; and APG273 for asthma and COPD. It also provides services related to engineering and optimizing antibodies with improved pharmacokinetics to reduce injection frequency for patients. The company was founded in 2022 and is based in San Francisco, California with an additional office in Waltham, Massachusetts. As of September 3, 2026, Apogee Therapeutics, Inc. operates as a subsidiary of AbbVie Inc.

Company Information

Company Name
Apogee Therapeutics, Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US03770N1019
CIK: 0001974640
Currency: USD
Full Time Employees: 261
Phone: (650) 394-5230
Fiscal Year End: December
IPO Date: Jul 14, 2023
Description:

Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulmonary disease and asthma; APG333, a half-life extended TSLP antibody; APG279, a combination therapy for atopic dermatitis; and APG273 for asthma and COPD. It also provides services related to engineering and optimizing antibodies with improved pharmacokinetics to reduce injection frequency for patients. The company was founded in 2022 and is based in San Francisco, California with an additional office in Waltham, Massachusetts. As of September 3, 2026, Apogee Therapeutics, Inc. operates as a subsidiary of AbbVie Inc.

Address:

One Letterman Drive, San Francisco, CA, United States, 94129-1492

People

Directors & Officers

Name Title Year Born
Dr. Michael Thomas Henderson M.D. CEO & Director 1989
Ms. Jane Pritchett V. Henderson Chief Financial Officer 1966
Dr. Carl Linden Dambkowski M.D. Chief Medical Officer 1985
Ms. Noel Kurdi Vice President of Investor Relations NA
Mr. Matthew Batters J.D. Chief Legal Officer & Corporate Secretary 1976
Ms. Emily Cox Senior VP & Head of People NA
Dr. Rebecca Dabora Ph.D. Chief Development Officer 1960
Ms. Wendy Aspden-Curran Senior Vice President of Clinical Operations NA
Dr. Drew Badger Ph.D. Senior VP and Head of Regulatory Affairs & Toxicology NA
Ms. Monica Forbes Senior Vice President of Finance 1976

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 08, 2026 Michael Thomas Henderson N/A Sale 20.00K $82.58 $1.65M
Apr 01, 2026 Carl Dambkowski N/A Sale 5.50K $84.84 $466.62K
Mar 11, 2026 Michael Thomas Henderson N/A Sale 20.00K $74.78 $1.50M
Mar 04, 2026 Carl Dambkowski N/A Sale 5.50K $71.06 $390.83K
Feb 11, 2026 Michael Thomas Henderson N/A Sale 20.00K $63.35 $1.27M
Feb 04, 2026 Carl Dambkowski N/A Sale 5.50K $65.79 $361.85K
Jan 22, 2026 Fairmount Funds Management Llc N/A Sale 1.75M $76.30 $133.53M
Jan 14, 2026 Michael Thomas Henderson N/A Sale 20.00K $81.11 $1.62M
Jan 07, 2026 Carl Dambkowski N/A Sale 18.70K $77.84 $1.46M
Dec 10, 2025 Michael Thomas Henderson N/A Sale 20.00K $75.38 $1.51M
Dec 04, 2025 Carl Dambkowski N/A Sale 10.90K $75.00 $817.50K
Dec 04, 2025 Michael Thomas Henderson N/A Sale 40.00K $75.01 $3.00M
Nov 13, 2025 Michael Thomas Henderson N/A Sale 20.00K $63.01 $1.26M
Nov 05, 2025 Carl Dambkowski N/A Sale 10.79K $55.07 $593.93K
Oct 01, 2025 Carl Dambkowski N/A Sale 5.11K $39.80 $203.38K
Sep 03, 2025 Carl Dambkowski N/A Sale 2.73K $37.87 $103.20K
Aug 06, 2025 Carl Dambkowski N/A Sale 2.73K $37.78 $102.95K
Jul 02, 2025 Carl Dambkowski N/A Sale 10.09K $45.09 $454.96K
Jun 04, 2025 Carl Dambkowski N/A Sale 2.73K $36.96 $100.72K
May 07, 2025 Carl Dambkowski N/A Sale 2.73K $35.75 $97.42K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
T. Rowe Price Investment Management,Inc. 10.30M Mar 31, 2026 13.62% $0.60 140.20%
FMR Inc 9.26M Mar 31, 2026 12.25% $0.04 12.61%
VR Adviser, LLC 8.49M Mar 31, 2026 11.23% $26.68 0.00%
BlackRock Inc 4.09M Mar 31, 2026 5.40% $0.01 7.97%
RTW INVESTMENTS, LLC 2.78M Mar 31, 2026 3.68% $2.33 2.58%
Vanguard Capital Management, LLC 2.50M Mar 31, 2026 3.31% $0.01 0.00%
HHG PLC 2.36M Mar 31, 2026 3.12% $0.09 14.45%
State Street Corp 2.16M Mar 31, 2026 2.86% $0.01 27.97%
Driehaus Capital Management LLC 1.92M Mar 31, 2026 2.54% $1.19 -12.04%
Paradigm Biocapital Advisors LP 1.58M Jun 30, 2026 2.08% $3.92 16.92%
Perceptive Advisors LLC 1.54M Mar 31, 2026 2.04% $2.53 -33.91%
Millennium Management LLC 1.49M Jun 30, 2026 1.97% $0.07 1,510.73%
Affinity Asset Advisors, LLC 1.28M Mar 31, 2026 1.70% $5.59 4.05%
Geode Capital Management, LLC 1.22M Mar 31, 2026 1.61% $0.01 14.94%
UBS Group AG 1.14M Mar 31, 2026 1.51% $0.01 17.39%
T. Rowe Price Associates, Inc. 1.14M Mar 31, 2026 1.51% $0.01 -7.60%
JPMorgan Chase & Co 1.11M Mar 31, 2026 1.47% $0.01 -19.12%
Vestal Point Capital LP 1.10M Mar 31, 2026 1.45% $2.59 100.00%
AllianceBernstein L.P. 990.30K Mar 31, 2026 1.31% $0.02 -9.45%
First Light Asset Management, LLC 930.29K Jun 30, 2026 1.23% $7.51 61.32%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 1.88M 2.48% ▲ 0.31% Jul 31, 2026
2 State Street® SPDR® S&P® Biotech ETF 1.27M 1.68% ▼ 1.06% Aug 31, 2026
3 iShares Russell 2000 ETF 1.15M 1.52% ▼ 0.57% Aug 31, 2026
4 BlackRock Event Driven Equity Instl 861.25K 1.14% ▲ 55.60% Jul 31, 2026
5 Vanguard Small Cap Index 676.20K 0.89% ▲ 0.26% Jul 31, 2026
6 Vanguard Institutional Extnd Mkt Idx Tr 644.41K 0.85% ▲ 0.48% Jul 31, 2026
7 Fidelity Blue Chip Growth Composite 613.75K 0.81% ▲ 0.00% Mar 31, 2026
8 First Trust Merger Arbitrage Cl I 535.46K 0.71% ▲ 0.00% Jun 30, 2026
9 Fidelity Small Cap Index 488.95K 0.65% ▲ 10.54% Jun 30, 2026
10 Janus Henderson Glb Life Scn I2 USD 431.38K 0.57% ▲ 23.35% May 31, 2026

Financial Highlights

Market Cap: $10.22B
EBITDA: $-322.12M
Book Value: $15.91
Earnings/Share: $-4.34
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -20.30%
ROE (TTM): -32.46%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $9.26B
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 62.20M
Shares Float: 58.44M
% Insiders: 2.32%
% Institutions: 110.81%
Short % Float: 7.28%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-1.42M
Gross Profit
subtotal
$-1.42M
SG&A
adjust
$-70.88M
R&D
adjust
$-214.71M
Operating Income
subtotal
$-285.60M
Other / Non-Operating Items
adjust
$29.75M
Net Income
subtotal
$-255.84M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about APGE.US!